Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
671 people get IMMU articles and Market Currents by email alert.
Get email alerts on IMMU »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
GlobeNewswire (May 8, 2013)
-
GlobeNewswire (May 7, 2013)
-
GlobeNewswire (Apr 25, 2013)
-
-
GlobeNewswire (Apr 10, 2013)
-
GlobeNewswire (Apr 9, 2013)
-
GlobeNewswire (Apr 8, 2013)
-
-
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
-
-
GlobeNewswire (Feb 27, 2013)
-
GlobeNewswire (Feb 25, 2013)
-
GlobeNewswire (Feb 22, 2013)
-
GlobeNewswire (Feb 21, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
Merck Facing Too Much Competition In HIV Drug PushFreedonia Freelance • Wed, Aug 22, 2012 -
-
-
-
5 Analyst-Backed Healthcare Small Caps Commanding Strong ProfitsZetaKap • Wed, Jul 18, 2012
-
-
-
-
-
-
-
-
Immunomedics' CEO Discusses F1Q13 Results - Earnings Call TranscriptFri, Nov 9, 2012 • 1 Comment
-
Immunomedics' CEO Discusses F4Q12 Results - Earnings Call TranscriptFri, Aug 24, 2012
-
GlobeNewswire (May 8, 2013)
-
GlobeNewswire (May 7, 2013)
-
GlobeNewswire (Apr 25, 2013)
-
GlobeNewswire (Apr 10, 2013)
-
GlobeNewswire (Apr 9, 2013)
-
GlobeNewswire (Apr 8, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Apr 1, 2013)
-
GlobeNewswire (Feb 27, 2013)
-
GlobeNewswire (Feb 25, 2013)
-
GlobeNewswire (Feb 22, 2013)
-
GlobeNewswire (Feb 21, 2013)
-
GlobeNewswire (Feb 7, 2013)
-
GlobeNewswire (Jan 25, 2013)
-
GlobeNewswire (Jan 8, 2013)
-
GlobeNewswire (Dec 21, 2012)
-
GlobeNewswire (Dec 12, 2012)
-
GlobeNewswire (Dec 11, 2012)
IMMU vs. ETF Alternatives
Company Description
Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 8, 6:53 PM Immunomedics (IMMU): FQ3 EPS of $0.11 beats by $0.21. Revenue of $1.7M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, May 7, 9:21 AM Immunomedics (IMMU) looks poised for a strong session after receiving three new patents. The first two relate to the use of conjugates of therapeutic agents for cancer and the combination of radioimmunotherapy and antibody-drug conjugates for improving cancer treatment respectively, while the third patent covers the use of PEGylated alpha interferon created by DNL for autoimmune disease treatment. Shares +4.96% premarket. (PR) Comment! [Healthcare, On the Move]
- Tuesday, April 9, 3:24 PM Immunomedics (IMMU +2%) trades up after announcing positive colorectal cancer treatment data earlier today. The drug developer says its proprietary antibody-drug conjugate, labetuzumab-SN-38, appears to be safe and reasonably well tolerated in patients with advanced colorectal cancer. Comment! [Healthcare, On the Move]
- Monday, April 8, 1:41 PM Immunomedics (IMMU -2.3%) says recent data presented at the 2013 Annual Meeting of the American Association for Cancer Research shows its Clivatuzumab-based blood test successfully identifies the difference between patients with pancreatic cancer and chronic pancreatitis. The study showed that test, which looks for a positive indication to indentify those who may have cancer, correctly identified two thirds of patients with early stages of the disease. Comment! [Healthcare, On the Move]
- Tuesday, April 2, 3:50 PM Immunomedics (IMMU +7.8%), which posted small gains early in the session after announcing a $16.7M arbitration settlement yesterday, rose sharply midday after SA contributor PropThink said the company's cash position now comfortably exceeds 2013's expected cash burn. Tuesday morning's modest gains allowed "investors to make an entrance without paying up for the improved balance sheet," PropThink said. 1 Comment [Healthcare, On the Move]
- Tuesday, April 2, 11:50 AM Immunomedics (IMMU +1.2%) moves up today after saying it's reached a $16.7M settlement through securities watchdog FINRA with its former broker Bank of America (BAC). The settlement resolves allegations the drug company had made related to investments in auction rate securities, for which it accused BAML of making false representations or omissions. Comment! [Healthcare, On the Move]
- Monday, April 1, 5:29 PM Immunomedics (IMMU) says it will receive a net $16.7M payment after agreeing to settle arbitration proceedings with a broker-dealer. Both the company and the broker are now released from all liabilities associated with the arbitration. Comment! [Healthcare]
-
Thursday, February 21, 5:43 PM
After-hours top gainers, as of 5:15 p.m.: ARUN +14%. WBMD +14%. ACTG +13%. FIRE +11%. BLOX +10%.
After-hours top losers: IMMU -7%. MDAS -6%. VVR -3%. VVUS -3%. PEGA -3%. Comment! [On the Move] - Monday, January 28, 10:40 AM Immunomedics (IMMU +3.3%) says its entered into an agreement with Algeta ASA (ALGZF.PK) for the development of a potential cancer treatment using IMMU's humanized anti-CD22 antibody, epratuzumab. Under the terms of the agreement, IMMU will provide clinical-grade antibody to Algeta, which has rights to evaluate epratuzumab for the treatment of cancer. Algeta will fund all preclinical and clinical development costs up to the end of Phase I testing. 1 Comment [Healthcare, On the Move, Global & FX]
- Wednesday, December 12, 2012, 4:08 PM Immunomedics (IMMU) says it's created two new classes of bispecific antibodies as the Dock-And-Lock complexes using the company's patented platform technology. These bispecific antibodies exhibited potent cell killing activity against lymphoma cell lines in vitro, with superior pharmacokinetic profiles and a higher effector functions. Comment! [Healthcare]
- Monday, December 10, 2012, 12:50 PM Immunomedics (IMMU -1.7%) reports that preclinical studies of its lead antibody drug candidate, epratuzumab, show the drug to have a distinct way of reducing the immune response of B cells. B cells are responsible for producing antibodies that attack the patient's own body in autoimmune diseases such as lupus. The study results were presented at the 54th Annual Meeting of the American Society of Hematology. Comment! [Healthcare]
- Wednesday, December 5, 2012, 1:38 PM Immunomedics (IMMU -3.5%) says it's developed two bispecific, hexavalent antibodies using it's patented technology for targeted therapies of various epithelial cancers. The two antibodies, designated as 1R-(E1)-(E1) and 1R-(15)-(15), were evaluated on three breast cancer cell lines of varying invasiveness, and one pancreatic cancer cell line, and demonstrated improved activity in controlling the spread and invasiveness of cancer cells in both cultures. Comment! [Healthcare]
- Thursday, August 23, 2012, 4:20 PM More on Immunomedics (IMMU): FQ4 misses across the board. Revenue was down Y/Y, due primarily to the milestone payment received during the prior year period. Bottom line numbers also suffered from higher than anticipated R&D spending, particularly on further clinical development of its pancreatic cancer drug clivatuzumab. 1 Comment [Healthcare, Earnings]
- Thursday, August 23, 2012, 4:04 PM Immunomedics (IMMU): FQ4 EPS of -$0.10 misses by $0.01. Revenue of $1M misses by $0.6M. (PR) Comment! [Earnings, Healthcare]
- Tuesday, January 31, 2012, 8:52 AM Shares of Immunomedics (IMMU) push 3.5% higher premarket after the firm nabs a broad-based patent from the USPTO related to antibody-based products for the treatment of cancer. Comment! [Healthcare, On the Move]
- Friday, January 20, 2012, 4:29 PM Immunomedics (IMMU -2.2%) finishes the day lower, despite reporting favorable results from the study of its proprietary humanized antibody, clivatuzumab tetraxetan, as a treatment for patients with advanced, inoperable, pancreatic cancer. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 8 replies
-
-
TruffelPig: Many of the biotech companies promise the next great thing in cancer. Few will succeed but I certainly wish them all the best.